LH Stock Analysis — LabCorp
Sector: Healthcare
AI Verdict
LabCorp trades at a low 13.8x forward P/E despite huge expected earnings growth, so you're getting a bargain price if its scale-driven moat keeps delivering.
Competitive Moat
LabCorp operates one of the largest diagnostic laboratory networks in the U.S., benefiting from scale-driven cost advantages and entrenched relationships with hospitals and insurers. Its nationwide logistics and data infrastructure make it difficult for smaller competitors to match its pricing and turnaround times.
Summary
LabCorp's forward P/E of 13.8x with 81.4% expected EPS growth makes it a standout among healthcare stocks for value and growth.
Where It Stands
Shares are up 16.26% over the past year with an RSI of 55.6 (neutral), and the stock trades at 13.8x next year's earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 55.6 — Neutral
- Trailing P/E: 25.1x
- Forward P/E: 13.8x
- PEG Ratio: 0.31
- Earnings Growth: +0.8%
- Revenue Growth: +0.1%
- Market Cap: $23.2B
- Dividend Yield: 0.01%
- 1-Year Return: 16.26%
- 52-Week High: $293.72
- 52-Week Low: $241.81
Analyst Consensus
23 Buy · 5 Hold · 0 Sell (28 analysts)
Bull Case
Analysts expect 81.4% EPS growth next year, yet the stock trades at just 13.8x forward earnings, making it cheap for the growth on offer.
Bear Case
If the P/E reverts to the sector median of 22x after the growth spike fades, upside is limited unless LabCorp sustains outsized earnings momentum.
Catalyst to Watch
Watch for quarterly earnings surprises — a miss on the 81.4% EPS growth expectation would likely trigger a sharp multiple compression.